Quest Diagnostics Incorporated (NYSE:DGX) Stock Holdings Raised by Tokio Marine Asset Management Co. Ltd.

Tokio Marine Asset Management Co. Ltd. raised its stake in Quest Diagnostics Incorporated (NYSE:DGX) by 8.9% in the 4th quarter, Holdings Channel.com reports. The firm owned 2,262 shares of the medical research company’s stock after acquiring an additional 185 shares during the period. Tokio Marine Asset Management Co. Ltd.’s holdings in Quest Diagnostics were worth $312,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently modified their holdings of DGX. NBC Securities Inc. bought a new stake in shares of Quest Diagnostics during the 3rd quarter valued at about $25,000. VisionPoint Advisory Group LLC grew its position in shares of Quest Diagnostics by 100.0% during the 3rd quarter. VisionPoint Advisory Group LLC now owns 218 shares of the medical research company’s stock valued at $27,000 after buying an additional 109 shares during the last quarter. BKM Wealth Management LLC bought a new stake in shares of Quest Diagnostics during the 4th quarter valued at about $29,000. FinTrust Capital Advisors LLC grew its position in shares of Quest Diagnostics by 1,100.0% during the 3rd quarter. FinTrust Capital Advisors LLC now owns 264 shares of the medical research company’s stock valued at $32,000 after buying an additional 242 shares during the last quarter. Finally, Alaska Permanent Fund Corp grew its position in shares of Quest Diagnostics by 79.3% during the 4th quarter. Alaska Permanent Fund Corp now owns 242 shares of the medical research company’s stock valued at $33,000 after buying an additional 107 shares during the last quarter. Institutional investors own 88.06% of the company’s stock.

Insider Activity at Quest Diagnostics

In related news, SVP Michael E. Prevoznik sold 5,611 shares of the stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $125.88, for a total transaction of $706,312.68. Following the completion of the sale, the senior vice president now directly owns 38,478 shares of the company’s stock, valued at $4,843,610.64. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, SVP Michael E. Prevoznik sold 5,611 shares of the stock in a transaction that occurred on Thursday, February 29th. The shares were sold at an average price of $125.88, for a total transaction of $706,312.68. Following the completion of the sale, the senior vice president now directly owns 38,478 shares of the company’s stock, valued at $4,843,610.64. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, SVP Michael E. Prevoznik sold 661 shares of the stock in a transaction that occurred on Thursday, February 22nd. The shares were sold at an average price of $126.14, for a total transaction of $83,378.54. Following the sale, the senior vice president now directly owns 40,206 shares of the company’s stock, valued at $5,071,584.84. The disclosure for this sale can be found here. Insiders sold a total of 15,150 shares of company stock valued at $1,913,202 over the last ninety days. Insiders own 0.79% of the company’s stock.

Quest Diagnostics Trading Down 0.9 %

Shares of NYSE:DGX opened at $134.26 on Monday. The company has a 50 day moving average of $129.09 and a 200-day moving average of $131.29. The firm has a market cap of $14.91 billion, a P/E ratio of 18.07, a P/E/G ratio of 2.92 and a beta of 0.91. Quest Diagnostics Incorporated has a twelve month low of $119.59 and a twelve month high of $146.85. The company has a current ratio of 0.97, a quick ratio of 1.20 and a debt-to-equity ratio of 0.59.

Quest Diagnostics (NYSE:DGX) last issued its quarterly earnings results on Tuesday, April 23rd. The medical research company reported $2.04 earnings per share for the quarter, topping analysts’ consensus estimates of $1.86 by $0.18. The company had revenue of $2.37 billion during the quarter, compared to analyst estimates of $2.29 billion. Quest Diagnostics had a net margin of 9.11% and a return on equity of 15.52%. The business’s revenue for the quarter was up 1.7% compared to the same quarter last year. During the same period in the prior year, the business posted $2.04 EPS. As a group, analysts anticipate that Quest Diagnostics Incorporated will post 8.78 earnings per share for the current fiscal year.

Quest Diagnostics Increases Dividend

The firm also recently announced a quarterly dividend, which was paid on Monday, April 22nd. Investors of record on Monday, April 8th were paid a dividend of $0.75 per share. The ex-dividend date of this dividend was Friday, April 5th. This is a positive change from Quest Diagnostics’s previous quarterly dividend of $0.71. This represents a $3.00 annualized dividend and a yield of 2.23%. Quest Diagnostics’s dividend payout ratio is currently 38.22%.

Analyst Ratings Changes

A number of brokerages recently weighed in on DGX. Leerink Partnrs reaffirmed a “market perform” rating on shares of Quest Diagnostics in a research report on Monday, February 26th. Truist Financial upped their target price on shares of Quest Diagnostics from $145.00 to $150.00 and gave the stock a “hold” rating in a research report on Wednesday, April 24th. StockNews.com upgraded shares of Quest Diagnostics from a “hold” rating to a “buy” rating in a research report on Thursday. Jefferies Financial Group upgraded shares of Quest Diagnostics from a “hold” rating to a “buy” rating and upped their target price for the stock from $140.00 to $155.00 in a research report on Wednesday, February 7th. Finally, UBS Group upped their target price on shares of Quest Diagnostics from $139.00 to $146.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 24th. Nine equities research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. Based on data from MarketBeat.com, Quest Diagnostics currently has a consensus rating of “Hold” and a consensus target price of $146.17.

Quest Diagnostics Company Profile

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.